Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE869.80-11.65 (-1.32 % )
PREV CLOSE (Rs.) 881.45
OPEN PRICE (Rs.) 870.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 292657
TODAY'S LOW / HIGH (Rs.)840.40 881.50
52 WK LOW / HIGH (Rs.)505 919
NSE869.80 -11.35 (-1.29 % )
PREV CLOSE(Rs.) 881.15
OPEN PRICE (Rs.) 870.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 869.80 (247 )
VOLUME 9473916
TODAY'S LOW / HIGH(Rs.) 840.50 881.80
52 WK LOW / HIGH (Rs.)504.75 919.2

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.03
Dividend Yield(%) 0.57
TTM EPS (Rs.) 23.07
P/E Ratio 37.71
Book Value (Rs.) 387.86
Face Value (Rs.) 2
MCap (Rs. in Mn) 394071.60
Price/Earning (TTM) 25.46
Price/Sales (TTM) 3.50
Price/Book (MRQ) 2.24
PAT Margin (%) 12.71
ROCE (%) 14.44
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Deshbandhu Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
22May05-22-2020$Lupin gets USFDA’s nod for Trientine Hydrochloride Capsules USP Lupin gets USFDA’s nod for
Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin has received approval for its Trientine Hydrochloride Cap..
22May05-22-2020$Lupin gains on getting USFDA’s nod for Trientine Hydrochloride Capsules USP Lupin gains on getting USFDA

Lupin is currently trading at Rs. 896.90, up by 11.15 points or 1.26% from its previous closing of Rs. 885.75 on the BSE.

The scrip opened at Rs. 881.10 and has touched a high and low of Rs. 897.70 and Rs. 875.60 respectively. So far 49768 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 906.35 on 27-Apr-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 897.55 and Rs. 833.80 respectively. The current market cap of the company is Rs. 40243.06 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.

Lupin has received approval for its Trientine Hydrochloride Capsules USP, 250 mg, from the United States Food and Drug Administration (USFDA), to market a generic equivalent of Syprine Capsules, 250 mg, of Bausch Health US, LLC. The product would be manufactured at Lupin’s Nagpur (Unit 1) facility, India.

Trientine Hydrochloride Capsules USP, 250 mg, are indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin is currently trading at Rs. 896.90, up by 11.15 points or..
19May05-19-2020$Lupin launches authorized generic version of Apriso Lupin launches authorized ge
Lupin has launched authorized generic version of Bausch Health’s Apriso (Mesalamine Extended-Release Capsules 0.375 g) in the U.S. Mesalamine Extended-Release Capsules 0.375 g (authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
 
Mesalamine Extended-Release Capsules 0.375 g, RLD: Apriso had an annual sales of approximately $290 million in the U.S. (IQVIA MAT March 2020).
 
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
Lupin has launched authorized generic version of Bausch Healthâ..
18May05-18-2020$Lupin gains on the bourses Lupin gains on the bourses

Lupin is currently trading at Rs. 854.50, up by 13.65 points or 1.62% from its previous closing of Rs. 840.85 on the BSE.

The scrip opened at Rs. 841.70 and has touched a high and low of Rs. 859.00 and Rs. 838.00 respectively. So far 55188 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 906.35 on 27-Apr-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 866.15 and Rs. 826.75 respectively. The current market cap of the company is Rs. 38596.81 crore.

The promoters holding in the company stood at 46.92%, while Institutions and Non-Institutions held 39.23% and 13.85% respectively.

Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the USFDA between January 13, 2020 and January 17, 2020.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin is currently trading at Rs. 854.50, up by 13.65 points or..
14May05-14-2020$Lupin receives EIR from USFDA for Vizag API Facility Lupin receives EIR from USFD
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the USFDA between January 13, 2020 and January 17, 2020.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
Lupin has received the Establishment Inspection Report (EIR) fr..
Financials More
Rs. in Millions
QTR Dec 19 ANNUAL 19
Net Profit-814.715388.3
Gross Profit -455.3 23423.7
Operating Profit 4856.231441.2
Net Sales 27159113563.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Dr. Reddys Lab (BSE)
 4073.80 (4.76%)
M.Cap ( in Cr)
67695.18
Abbott India (BSE)
 16728.05 (0.80%)
M.Cap ( in Cr)
35545.94
Astrazeneca Pharma I (BSE)
 3044.50 (4.52%)
M.Cap ( in Cr)
7611.25
Divis Lab (BSE)
 2395.75 (4.92%)
M.Cap ( in Cr)
63599.64
Solara Active Pharma (BSE)
 517.20 (9.70%)
M.Cap ( in Cr)
1388.95
Shareholding Pattern More
FI/BANKS/INSURANCE 5.94 %
PROMOTERS 46.92 %
NON-INSTITUTION 13.85 %
MUTUAL FUNDS/UTI 10.14 %
GOVERNMENT 0.28 %
FII 0 %
F & O Quotes